Diabetes & Metabolism
Diabetes mellitus and hypertension are two of the most common diseases in Westernized, industrialized civilizations, and the frequency of both diseases increases with increasing age. Diabetes mellitus is characterized by elevated blood glucose levels (hyperglycemia) resulting from defects in insulin secretion, insulin action or both, and associated with a considerably increased cardiovascular risk, peripheral vascular diseases, stroke, retinopathy, and nephropathy. Two types of diabetes mellitus are recognized based on the presumed etiology. In type 1 diabetes, the body fails to produce insulin as a result of an auto-immune reaction that destroys the islet cells in the pancreas that produce insulin, and daily insulin injections are required. Type 1 diabetes is usually diagnosed during childhood or early adolescence and it affects about 1 in every 600 children. Type 2 diabetes is the result of failure to produce sufficient insulin and insulin resistance. Elevated blood glucose levels are managed with reduced food intake, increased physical activity, and eventually oral medications or insulin. Type 2 diabetes is typically diagnosed during adulthood. However with the increasing incidence of childhood obesity and concurrent insulin resistance, the number of children diagnosed with type 2 diabetes has also increased worldwide.
The hallmark of hypertension in type I and type II diabetics appears to be increased peripheral vascular resistance. Increased exchangeable sodium may also play a role in the pathogenesis of blood pressure in diabetics. Evidence is accumulating that insulin resistance, or hyperinsulinemia, may play a key role in the pathogenesis of hypertension in both subtle and overt abnormalities of carbohydrate metabolism. Population studies suggest that elevated insulin levels, which often occurs in type II diabetes mellitus, is an independent risk factor for cardiovascular disease. Other cardiovascular risk factors in diabetic individuals include abnormalities of lipid metabolism, platelet function, and clotting factors.
Axon ID | Name | Description | From price | |
---|---|---|---|---|
1730 | (+)-Kifunensine | α-mannosidase inhibitor | €120.00 | |
2830 | (R)-CE3F4 | Potent inhibitor of EPAC1 | €120.00 | |
3743 | (R)-HTS-3 hydrochloride | First potent, selective, and cell-active LPCAT3 inhibitor | €150.00 | |
2537 | 1,5-Isoquinolinediol | PARP1 inhibitor and neuroprotective agent | €50.00 | |
2175 | 3PO | Inhibitor of HIF-1-induced PFKFB3, an enzyme with a key role in glycolysis. | €65.00 | |
1909 | A 1070722 | Selective inhibitor of GSK-3 | €95.00 | |
2059 | A 922500 | Highly potent and selective diacylglycerol acyltransferase 1 (DGAT-1) inhibitor | €105.00 | |
1873 | Abiraterone | Inhibitor of CYP17A1 | €90.00 | |
1874 | Abiraterone acetate | Prodrug of Abiraterone; Inhibitor of CYP17A1 | €90.00 | |
2552 | Adjudin | Non-hormonal male contraceptive with anti-proliferative activity | €125.00 | |
2746 | AG-120 | IDH1 mutant enzyme inhibitor | €125.00 | |
2745 | AG-221 | IDH2 mutant enzyme inhibitor | €95.00 | |
2122 | AGI 5198 | Inhibitor of R132 mutant isocitrate dehydrogenase 1 (IDH1) | €60.00 | |
2274 | AGI 6780 | Potent and selective inhibitor of the tumor-associated mutant IDH2 (R140Q) | €90.00 | |
2269 | AK 1 | Potent inhibitor of SIRT with good selectivity for SIRT2 over SIRT1 and SIRT3 | €90.00 | |
2270 | AK 7 | Potent, brain-permeable and selective inhibitor of SIRT2 | €90.00 | |
3310 | Alogliptin benzoate | Potent, highly selective and orally active DPP-4 inhibitor | €65.00 | |
2883 | APPA | Aldose reductase inhibitor | €105.00 | |
2819 | APX-115 | First-in-class pan-NADPH oxidase (Nox) inhibitor | €125.00 | |
2167 | AR-A 014418 | ATP-competitive GSK-3 inhibitor | €85.00 | |
2839 | AS 1842856 | Inhibitor of the Forkhead box protein O1 (FOXO1) | €95.00 | |
2578 | ASB14780 | Potent, orally available inhibitor of cPLA2α; antiinflammatory drug | €130.00 | |
2276 | Atglistatin | Potent and selective inhibitor of adipose triglyceride lipase (ATGL) | €90.00 | |
2043 | Atorvastatin calcium | Inhibitor of HMG-CoA reductase | €60.00 | |
2960 | ATR-101 | Potent, selective, and orally active ACAT1 inhibitor | €145.00 | |
2692 | AX-024 hydrochloride | T cell receptor inhibitor | €125.00 | |
5051 | Axon Ligands™ Cell signaling and Oncology compound library | Axon Ligands™ Cell signaling and Oncology compound library | Inquire | |
5053 | Axon Ligands™ Stem cell compound library | Axon Ligands™ Stem cell compound library | Inquire | |
2171 | AZD1080 | Selective inhibitor of GSK-3α and GSK-3β | €90.00 | |
3771 | AZD2858 | Potent and highly selective Glycogen Synthase Kinase-3β inhibitor | €95.00 |